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Substance use, medication adherence and outcome one year following a first episode of 
psychosis 
 
ABSTRACT 
 
Both substance use and poor medication adherence are associated with poor outcome in 
psychosis. To clarify the contributions of substance use and poor medication adherence to poor 
outcome in the year following a first episode of psychosis, 205 patients were evaluated for use of 
tobacco, alcohol, cannabis and stimulants at their psychosis onset, and in a 1-year follow-up. Data 
on medication adherence and symptom remission were also collected. Patients had high rates of 
overall substance use before (37-65%) and after psychosis onset (45-66%). 44% showed poor 
medication adherence and 55% did not reach remission from psychosis. Nicotine dependence and 
cannabis use after psychosis onset significantly predicted both poor medication adherence and non-
remission, and poor medication adherence mediated the effects of these substances on non-
remission. In conclusion, medication adherence lies on the causal pathway between nicotine 
dependence and cannabis on the one hand and non-remission on the other.  
 
Keywords: First Episode Psychosis, Substance use, Cannabis use, Nicotine dependence, Medication 
adherence, Remission 
 
 
 
 
 
 
 
  
 
1. INTRODUCTION 
 
A number of studies have evaluated the impact that poor adherence to antipsychotic 
medication has on quality of life and hospitalizations in patients with psychosis (Gray et al., 2002; 
King et al., 2014, Park et al., 2014). Thus, poor medication adherence in patients following the first 
episode of psychosis (FEP) is associated with more frequent readmissions (Caseiro et al., 2012; 
Verdoux et al., 2000), and a greater risk of relapse (Kahn et al., 2008; Malla et al., 2006; Novak-
Grubic and Tavcar, 2002). 
Rates of poor adherence in FEP studies have been reported to range up to 71% (Hill et al., 
2010; Levy et al., 2012; Miller et al., 2011). Use of substances, including cannabis and alcohol, has 
been found in several studies to be associated with poor medication adherence (Faridi et al., 2012; 
Hill et al., 2010; Lambert et al., 2010; Miller et al., 2009), as have a number of other demographic 
and clinical factors (Hill et al., 2010; Lambert et al., 2010). Furthermore, comorbid substance use 
has emerged as one of the greatest obstacles to the effective treatment of persons with psychosis; 
substance use is a risk factor for both poor medication adherence and dropout from treatment. 
Moreover, some studies suggest a dose-response relationship between severity of substance use and 
medication adherence rates (Dixon, 1999; Miller et al., 2009; Wade et al., 2007). 
Two major limitations of the published data on substance use disorder and poor medication 
adherence are the small sample size of most studies and the narrow focus, usually on use of only 
one substance. In addition, the relation of poor adherence to tobacco smoking has not to date been 
investigated.  This is important given that tobacco smoking is highly prevalent among psychotic 
patients, and there have been recent suggestions that tobacco smoking may be a risk factor for both 
onset (Gurillo et al., 2015) and outcome (Krishnadas et al., 2012) of psychosis. 
In a one year follow-up of first episode psychosis patients, we obtained detailed information 
on the most commonly used substances among psychiatric patients, including tobacco, alcohol, 
cannabis and stimulants (such as amphetamines) both at baseline and during their subsequent 
clinical contact. Therefore the strength of our study is the ability to address the following 
hypotheses: 1. substance use following illness onset (tobacco, alcohol, cannabis and other 
stimulants) impairs medication adherence; 2. Substance use is associated with poor outcome at 1 
year follow-up, and poor medication adherence mediates this effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
2. MATERIALS AND METHODS 
  
2.1.   Study design and sample 
Participants were recruited as part of the Biomedical Research Centre (BRC) Genetics and 
Psychosis (GAP) and the Physical Health and Substance Use Measures (PUMP) studies carried out 
at the Institute of Psychiatry, Psychology and Neuroscience, London (Di Forti et al., 2009). All 
patients presenting to the Adult Psychiatric services (18 years<age<65 years) of the South London 
and Maudsley NHS Foundation Trust between December 2005 and October 2010 with their first 
episode of psychosis (FEP) who gave consent, were recruited into the study. Eligibility was 
determined through examination of the clinical notes of new admissions and consultation with 
clinical teams, and then validated by the Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN) interview (WHO, 1992). Inclusion criteria required that patients had 7 or more 
consecutive days of psychotic symptom(s) and were presenting to the psychiatric services for the 
first time with psychosis. Patients with an IQ<70, poor English fluency, and with a known or 
suspected organic cause for psychosis were excluded.  
The data presented here are based on the subset of the whole GAP/PUMP sample (N = 
205/461, 44%) on whom we were able to complete follow-up assessments for the year after the 
first contact with psychiatric services for psychotic disorder, and obtain satisfactory data on 
substance use and medication adherence. The most common reasons for attrition during the follow-
up period were disengagement from clinical team after first hospitalization/contact with mental 
health services (N = 62, 13.4%) or insufficient/unavailable clinical information on the entire 
follow-up period because of disengagement from mental health services at some point during the 
one year follow-up period (N = 137, 29.7%). Other reasons for drop out included: a) left the UK (N 
= 16, 3.5%) or transferred to other mental health services within the UK (N = 10, 2.2%); b) death 
(non-suicide) (N = 11, 2.4%) or suicide (N = 3, 0.7%). Moreover, a small proportion of patients (N 
=17, 3.7%) were excluded from the study because they were found to have already been treated 
with antipsychotics before enrolment in the study.    
 
2.2.   Baseline assessments 
2.2.1. Clinical and socio-demographic measures 
Baseline information about age, gender, self-reported ethnicity, relationship status, 
employment status and level of education was collected using the Medical Research Council Social 
Scale (MRCSS; Mallett et al., 2002). Diagnosis was made according to DSM-IV/ICD-10 criteria 
using the Operational Criteria OPCRIT (McGuffin et al., 1991) based on both the clinical notes and 
the data collected with the SCAN (WHO, 1992) in the month following the first contact with 
psychiatric services for psychosis. All diagnoses were made by qualified psychiatrists and clinical 
researchers, who attended training and OPCRIT intra-class correlation assessment (0.70 ≤ 
Cronbach’s α ≤ 1). Diagnoses were combined in two main categorical groups: 1. non-affective 
psychosis (ICD10 codes: F20-F29; WHO, 1992) and 2. affective psychosis (ICD 10 codes: F30-
F33; WHO, 1992).  
2.2.2. Substance use evaluation 
 Subjects who reported tobacco use were interviewed using the Fagerström Test for Nicotine 
Dependence (FTND; Heatherton et al., 1991). This questionnaire is a standard instrument for 
assessing the intensity of physical addiction to nicotine in the general population and provides an 
ordinal measure of nicotine dependence related to cigarette smoking. It contains six items that 
evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. In the 
FTND, yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The 
items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more 
intense is the patient's physical dependence on nicotine. Subjects with FTND scores ≥5 were 
classified as nicotine-dependent. 
Similarly, participants who reported alcohol use were interviewed using the Alcohol Use 
Disorders Identification Test (AUDIT; Babor et al., 1989). This questionnaire is a reliable and 
simple screening tool which is sensitive to early detection of risky and high risk (or hazardous and 
harmful) drinking. It has ten questions on alcohol consumption (1 to 3), dependence (4 to 6), and 
the consequences or problems related to drinking (7 to 10). Questions 1 to 8 are scored on a five-
point scale from 0, 1, 2, 3, and 4. Questions 9 and 10 are scored on a three-point scale from 0, 2 and 
4. The maximum total score is 40. Evidence from studies determining the validity and reliability of 
the AUDIT for detecting problem drinking in a population of FEP indicate that the AUDIT 
functions best with a cut-off score of 10 (sensitivity, 85%; specificity, 91%; Cassidy et al., 2008). 
Subjects with AUDIT scores ≥10 were classified as problem drinkers in this study. 
FEP patients were administered the Cannabis Experience Questionnaire modified version 
(CEQMV; Colizzi et al., 2015a; Colizzi et al., 2015b; Di Forti et al., 2012) at baseline. This 
questionnaire provides information on lifetime use of cannabis, tobacco, stimulants and other drugs 
at enrollment. The CEQmv allows detailed assessment of patterns of cannabis and as well as use of 
other illicit drugs including stimulants, including age at first use, frequency and duration of use, and 
the specific type of cannabis used. 
 
2.3.   Case-tracing procedure 
The one-year follow-up period was taken as the date of first contact with mental health 
services of the South London and Maudsley Mental Health NHS Foundation Trust (SLAM) for 
psychosis to the date exactly one year later using the clinical records held on the SLAM electronic 
Patient Journey System (ePJS). All of the following measures were completed by a researcher 
retrospectively from the electronic mental health records system (ePJS of SLAM).  
 
2.4.   Follow-up assessments 
Clinical, socio-demographic and substance use data were collected with the Follow-up 
Psychiatric and Personal History Schedule (FU-PPHS). The PPHS is a schedule to record 
information about mental state, general behavior, substance use, events and personal history of the 
patient during a follow-up period; information can be obtained from patients, informants, case notes 
and other records (Janca and Chandrashekar, 1995). Researchers involved in rating the PPHS at 
follow-up achieved an excellent intra-class correlation (> 0.90) on all PPHS items when duplicate 
ratings were compared.  
2.4.1. Clinical assessment: medication adherence and remission 
 Information on medication adherence and remission during the one year follow-up was 
extracted from the PPHS (Janca and Chandrashekar, 1995). In the PPHS, poor adherence is defined 
as: 1=lapses of 3 or more days more than once; 2= not taking any prescribed medication. Remission 
is operationally defined as: absence of positive, negative or disorganized symptoms for at least 30 
days.  
2.4.2. Substance use evaluation 
Substance use over the one year follow-up was scored using FTND (Heatherton et al., 
1991), AUDIT (Babor et al., 1989), and CEQMV (Colizzi et al., 2015a; Colizzi et al., 2015b; Di Forti 
et al., 2012), in the same manner as for baseline.  
 
2.5.   Ethical approval 
This study was granted ethical approval by the South London and Maudsley and Institute of 
Psychiatry Local Research Ethics Committee. All patients included in the study gave informed 
written consent to be assessed at baseline, to be re-contacted at follow-up; they gave permission to 
access their clinical records and the publication of data originating from the study. 
 
2.6.   Data Analysis 
ANOVAs and χ2 were used to evaluate the relation between sample characteristics [socio-
demographic measures (age, gender, ethnicity, relation status, employment status, and level of 
education) and diagnosis (affective/non-affective psychosis)] and substance use [yes/no; nicotine 
dependence, problem drinking, cannabis use, and stimulant use]. Also ANOVAs and χ2 were used 
to analyze the association between sample characteristics and medication adherence during the one 
year follow-up.  
According to Byron and Kenny (1986), evidence for mediation requires the satisfaction of 
four criteria. The first two criteria require that a significant association between the independent 
variable and the mediator (path a) and the independent variable and the outcome variable (path c) be 
established. In order to evaluate these criteria, multivariable logistic regressions, with nicotine 
dependence, problem drinking, cannabis use, and stimulant use (yes/no) as independent variables, 
were used to test the effect of each substance before psychosis onset (premorbid use) on medication 
adherence (path a) and remission (path c) during the one year follow-up after adjusting for socio-
demographic measures (age, gender, ethnicity, relation status, employment status, and level of 
education). Similar analyses were performed to test the associations between each substance use 
after psychosis onset (use in the one year follow-up period) and medication adherence (path a) as 
well as between each substance use after psychosis onset and remission (path c).  
The third criterion requires that the mediator predicts the dependent variable even when the 
independent variable is controlled for (path b). In order to evaluate this criterion, logistic 
regressions were used to test the effect of medication adherence on remission (path b) during the 
one year follow-up after adjusting for socio-demographic measures. The same analysis was 
performed again after adjusting also for substance use. The final criterion requires assessing the 
degree of attenuation between the independent and outcome variables after adjustment for the 
mediator (path c'). A complete mediating effect occurs when the association between the 
independent and the dependent variable is eliminated when the mediator is controlled for. For this 
criterion, multivariable logistic regressions, with nicotine dependence, problem drinking, cannabis 
use, and stimulant use (yes/no) as independent variables, were used to test the effect of each 
substance on remission during the one year follow-up after adjusting for socio-demographic 
measures and medication adherence. After standardizing each regression coefficient (multiplied by 
the standard deviation of the predictor variable and divided by the standard deviation of the 
outcome variable), the decomposition has been computed. The Sobel test was utilized to evaluate 
the statistical significance of the mediation effect (Sobel and Leinhardt, 1982). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. RESULTS 
 
3.1.   Socio-demographic characteristics 
Out of 205 FEP patients on whom we obtained complete data at 1 year, 63.4% were male. 
There were no significant differences between those in whom complete data were obtained (N = 
205) and those in whom it was not (N = 256) in terms of gender, age at first contact, ethnicity, 
relationship status, employment status, education level and diagnosis (all p > 0.1). The average age 
at first contact with psychiatric services for psychotic disorder was 29.6 years (± SD, ± 9.9 years). 
35% of the FEP were White, 43% Black African/Caribbean and 22% Asian/other. The majority of 
the patients were single (73.7%) and unemployed (63.9%), and had completed only secondary 
education (60.5%). Using the OPCRIT diagnostic assessment, 75.6% of the patients satisfied ICD-
10 criteria for non-affective psychosis (F20-F29; Table 1).  
 
3.2.   Substance use, medication adherence, and remission 
At baseline 53.2% reported premorbid nicotine dependence, 40.5% premorbid problem 
drinking, 65.4% premorbid cannabis use, and 36.6% premorbid stimulant use (Table 2). Neither 
socio-demographic characteristics nor diagnosis (non-affective vs. affective psychosis) was 
associated with any type of substance use at baseline (all p > 0.1).  
The 1 year follow-up evaluation revealed that 59.5% of the FEP were dependent on nicotine, 
42% problem drinkers, 66.3% were cannabis users, and 44.9% stimulant users (Table 2). Neither 
socio-demographic characteristics nor diagnostic categories were associated with any type of 
substance use during the follow-up (all p > 0.1).  
43.9% of the patients adhered poorly to their pharmacological treatment at some point 
during the first year of following their first episode of psychosis (at least two lapses of 3 or more 
days; Table 2). Neither socio-demographic characteristics nor diagnosis categories were associated 
with medication adherence during the follow-up period (all p > 0.1). More than 50% of the patients 
failed to satisfy PPHS criteria for remission (Table 2). Neither socio-demographic characteristics 
nor diagnostic categories were associated with remission status (all p > 0.1). 
 
3.3.   Mediation analyses 
No single substance use before the first episode of psychosis reached significance for an 
association with medication adherence during the follow-up (path a). Similarly, substance use 
before the psychosis onset was not associated with remission status at follow-up (path c). Therefore, 
the mediation analysis was terminated. 
Substance use in the year after psychosis onset was associated with increased probability of 
poor medication adherence during the follow-up (path a). In particular, the analysis showed 
significant main effects of nicotine dependence (OR=2.18), cannabis use (OR=2.86), and stimulant 
use (OR=2.63) on the odds of being non adherent to treatment. In contrast, the OR failed to reach 
significance for an association between problem drinking and poor medication adherence (Table 3).  
Substance use in the first year after psychosis onset was associated with increased 
probability of non-remission during the one year follow-up (path c). In particular, the analysis 
showed significant main effects of nicotine dependence (OR=2.13) and cannabis use (OR=2.60) on 
probability of not achieving remission. In contrast, the ORs failed to reach significance for an 
association between problem drinking and non-remission as well as between stimulant use and non-
remission (Table 3).  
Medication adherence significantly predicted remission during the one year follow-up (path 
b). In particular, patients with poor medication adherence showed a six-fold increased probability of 
non-remission of their psychosis when compared with patients with good medication adherence 
(Table 4). When substance use in the one year follow-up period was added in to this model, the 
association between medication adherence and remission was still significant (Table 4).  
Following Baron and Kenny’s approach to mediation, the first three criteria were satisfied 
only for nicotine dependence and cannabis use post onset. Therefore, the mediation analysis was 
terminated for problem drinking and stimulant use. In order to test for the final criterion, the 
associations between nicotine dependence after psychosis onset and non-remission as well as 
between cannabis use and non-remission were adjusted for medication adherence (path c'). When 
medication adherence was added in to the model, even if increased, the ORs failed to reach 
significance (Table 3). Sobel tests for mediation showed that medication adherence was a 
significant mediator of the relationship between nicotine dependence and remission (z = 2.02, p = 
.04; Figure 1) as well as that between cannabis use and remission (z = 2.12, p = .03; Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. DISCUSSION 
 
To our knowledge, this is the first study to systematically examine the association between 
use of the most common substances before and after psychosis onset, and clinical outcome over a 
one-year period in patients suffering their first episode of psychosis. The results indicate that both 
nicotine dependence and use of cannabis in the first year after psychosis onset affect medication 
adherence; furthermore, poor medication adherence is a strong predictor of non-remission. Finally, 
nicotine dependence and cannabis use in the first year after psychosis onset are associated with 
increased probability of non-remission during the one year follow-up, and medication adherence 
mediates these effects. 
Our sample was characterized by high rates of substance use, both at time of the diagnosis 
and during the one year follow-up. The data are consistent with the literature, even if the prevalence 
of substance use we found is higher because we included any kind of use and not only categorically 
defined substance use disorders (Addington and Addington , 2007; Myles et al., 2012; Van Mastrigt 
et al., 2004). As in many previous studies (Coldham et al., 2002; Levy et al., 2012; Miller et al., 
2011; Novak-Grubic and Tavcar, 2002; Verdoux et al., 2000), more than 40% of patients recruited 
showed poor adherence to their pharmacological treatment during the one year follow-up, but 
contrary to the published literature, this was not predicted by socio-demographic characteristics 
(Cotton et al., 2009; Perkins et al., 2008). Our findings are however in line with the previous 
literature (Alvarez-Jimenez et al., 2012) in showing an increased risk of non-remission due to poor 
medication adherence. 
Our study evaluated the impact of substance use, both premorbidly and after psychosis 
onset, on medication adherence. Our findings indicate that premorbid substance use does not affect 
medication adherence during the one year follow-up. However, substance use during the year after 
psychosis onset significantly predicted poor medication adherence at follow-up. Lastly we clearly 
showed that substance use increases the risk of non-remission (Alvarez-Jimenez et al., 2012), with a 
more than 2-fold increased likelihood of not achieving remission for nicotine dependent and 
cannabis using patients. These findings are novel in demonstrating that this association is mediated 
by poor medication adherence, implying that medication adherence lies on the causal pathway 
between substance use and non-remission.  
Although nicotine dependence appears to be a risk factor for psychosis (Gurillo et al., 2015) 
and a predictor of worse clinical and social outcome in psychosis patients (Krishnadas et al., 2012), 
why this should be is still unclear (Gurillo et al., 2015; Krishnadas et al. 2012). One possibility is 
that chronic nicotine use dysregulated dopamine signaling (Brody et al., 2010). Our results indicate 
a role for medication adherence in the association between nicotine dependence and non-remission. 
Research suggests that certain personality factors may be involved in tobacco use and dependence, 
such as low conscientiousness and high levels of neuroticism (Zvolensky et al., 2015). One might 
therefore hypothesize that these personal characteristics make nicotine dependent patients less 
likely to adhere to medication.  
Cannabis use has been consistently indicated as a risk factor for schizophrenia (Di Forti et 
al., 2009), and a review has indicated relapse and poor medication adherence as the two most 
relevant clinical outcomes affected by cannabis use in psychosis (Zammit et al., 2008). Our results 
clarify the nature of this relationship, suggesting a mediation effect of medication adherence in the 
association between cannabis use and non-remission. Several studies offer a possible 
neurobiological explanation for the increased non-adherence in cannabis users. Chronic cannabis 
use leads to low striatal dopamine synthesis and release, and there is much evidence that these low 
dopamine levels drive craving for further drug use (Bloomfield et al., 2014; Murray et al., 2014). 
Antipsychotics block dopamine and therefore may compound this low striatal dopamine leading to 
greater craving as well as anhedonia, and consequent unwillingness to take further antipsychotics.  
It is unclear whether stopping smoking or cannabis use would mitigate the increased liability 
of poor medication adherence and non-remission showed by patients continuing to smoke or use 
cannabis after their psychosis onset. However, some hope comes from the finding that premorbidly 
nicotine dependent and cannabis using patients were not differentiable from never smokers and 
cannabis-naïve subjects in terms of medication adherence and odds of remission. In contrast, our 
results show that nicotine dependence and cannabis use after psychosis onset are associated with a 
higher probability of having non-remission from a first episode of psychosis and should be treated 
as risk factors for poor medication adherence and subsequent poor clinical outcome. Furthermore, 
nicotine dependence and cannabis use have been shown to greatly elevate odds of having a poor 
general health in later life among psychosis patients. In particular, smoking is 2 to 3 times more 
frequent in psychosis patients compared to healthy subjects and is considered to contribute 
significantly to the elevated rates of cardiovascular morbidity and mortality among patients with 
psychosis (Depp et al., 2015). Similarly, a review of clinical studies has found cannabis use to 
impact negatively on a number of outcomes, including social functioning, physical health, rates and 
duration of hospitalization (Atakan, 2008). Thus, services caring for patients suffering their first 
episode of psychosis should invest resources in the treatment of their substance use to improve 
clinical outcomes and reduce subsequent burden on services.  
 
4.1.   Strengths and limitations 
The main strengths of the present study are its prospective longitudinal design and its 
sample size. Moreover, it analyses all the most common used substances, both before and after 
psychosis onset. Instead, data collection methods at baseline and follow-up is a potential pitfall of 
the study, such that information collected at baseline was self-reported, while at follow-up, this 
information was obtained by clinical notes. This may have an impact on the comparability of these 
data. For example, self-report data may be more prone to recall bias even if it is less likely to occur 
when data are collected at the onset of the illness. Moreover, patients might be reluctant to disclose 
their substance use, though if true the latter would underestimate the magnitude of the effect 
reported. In contrast, the presence of multiple observers and multiple assessments at follow-up has 
ensured the reliability of data collected, also in light of the significantly high consistency amongst 
the researchers involved in this study. Moreover, having patient clinical information stored 
electronically increases the availability of data, helping public health researchers to produce 
research that is beneficial to society and speeding the process of identifying evidence-based best 
practices. However, despite the benefits associated with using clinical records data for research, 
there are also great challenges. Because clinical records are designed to support health care 
provision, they are not structured in a way that facilitates the research process. In fact, providers can 
decide where to put information; information may be entered in free-text form instead of being 
entered in defined fields or picked from a structured list of medical terms; providers can use 
different terms for the same information (lack of standardization); information may not be stored in 
a way that is readily searchable and data that are not important to clinical care may be missing. 
Also, having only one short-midterm follow up point represents another limitation of this study. 
Finally, cannabis and tobacco are often consumed together in the same joint and there is 
accumulating evidence of a common underlying biological vulnerability to both substances 
(Agrawal et al., 2012). Even if this study aims statistically to assess the independent effect of each 
substance on both medication adherence and remission, further research is needed to definitively 
disentangle their independent contribution on patients’ clinical outcome.  
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